The groundbreaking therapy of tirzepatide peptide represents a significant development in the handling of type 2 diabetes. Distinct from existing therapies, tirzepatide targets two pathways – glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) – leading to enhanced blood sugar control and possible reduction in… Read More